Skip to content

BreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders

BreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders (B-GLAD)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05574140
Acronym
B-GLAD
Enrollment
84
Registered
2022-10-10
Start date
2022-07-15
Completion date
2025-09-15
Last updated
2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder, Oxygenation Sensitive CMR

Brief summary

This study aims to view variations in MRI measurements of the heart and the brain in people with anxiety versus healthy volunteers. The MRI measurements used will be Oxygenation-Sensitive Cardiac MRI (OS-CMR), a recent type of MRI which is safe, fast, and non-invasive.

Detailed description

The investigators will prospectively analyze OS-CMR data from patients with a generalized anxiety disorder from one site. The investigators will observe how an anxiety disorder affects the OS-CMR data. In a follow-up MRI scan, the investigators will look at the OS-CMR of a subgroup who have anxiety disorder and are also undertaking cognitive behavioural therapy to asses how and if this therapy affects the OS-CMR data.

Interventions

DIAGNOSTIC_TESTCardiac MRI

The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

Patient population: Age 18-55, * Confirmation of an anxiety disorder as identified by the PSWQ, * No known, current or history, of significant medical conditions that may affect or directly involve the neurological, cardiovascular or respiratory system (except anxiety and depression) * Non-smoker Healthy Volunteers: * Age 18-55 * No known, current or history, of significant medical conditions that may affect or directly involve the neurological, cardiovascular or respiratory system * Non-smoker

Exclusion criteria

* General MRI contraindications: pacemakers, defibrillating wires, implanted defibrillators, intracranial aneurysm clips, metallic foreign bodies in the eyes, pregnancy * History of significant neurological disease or illness that is not anxiety (e.g. Dementia, stroke) * Hemodynamically unstable conditions * Significant or uncontrolled arrhythmias * Severe pulmonary disease * Recent (\<90 days) myocardial infarction * Recent (\<90 days) surgery or coronary intervention * Consumption of caffeine (caffeinated beverages, coffee, tea, cocoa, chocolate) within 12h of the exam * Use of benzodiazepines or other short-acting anxiety medications (\<1 day)

Design outcomes

Primary

MeasureTime frameDescription
Change in Signal IntensityBaselineChange in signal intensity between the baseline signal intensity and the signal intensity at 30 seconds of breath hold

Countries

Canada

Contacts

Primary ContactMayssa Moukarzel
mayssa.moukarzel@mail.mcgill.ca(514) 5530-7385
Backup ContactElizabeth Konidis, Master
elisavet.konidis@muhc.mcgill.ca514-934-1934

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026